Hillman Capital Management Inc. Has $5.69 Million Position in CVS Health Corporation $CVS

Hillman Capital Management Inc. decreased its stake in shares of CVS Health Corporation (NYSE:CVS) by 13.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 71,685 shares of the pharmacy operator’s stock after selling 10,674 shares during the quarter. CVS Health comprises 3.6% of Hillman Capital Management Inc.’s investment portfolio, making the stock its 4th biggest position. Hillman Capital Management Inc.’s holdings in CVS Health were worth $5,689,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Kingsview Wealth Management LLC boosted its holdings in shares of CVS Health by 316.2% during the 3rd quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock worth $7,873,000 after buying an additional 79,340 shares during the period. Intech Investment Management LLC boosted its holdings in shares of CVS Health by 50.3% during the 3rd quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock worth $6,526,000 after buying an additional 28,953 shares during the period. Hamlin Capital Management LLC bought a new stake in shares of CVS Health during the 4th quarter worth about $160,844,000. Cresset Asset Management LLC boosted its holdings in shares of CVS Health by 56.8% during the 3rd quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock worth $2,675,000 after buying an additional 12,849 shares during the period. Finally, Capitolis Liquid Global Markets LLC bought a new stake in shares of CVS Health during the 3rd quarter worth about $11,308,000. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

NYSE CVS opened at $100.71 on Wednesday. The firm has a 50-day moving average price of $88.00 and a two-hundred day moving average price of $81.10. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $102.77. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $128.50 billion, a P/E ratio of 44.37, a P/E/G ratio of 0.99 and a beta of 0.62.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts anticipate that CVS Health Corporation will post 7.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Morgan Stanley boosted their price objective on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday, June 4th. HSBC boosted their price objective on shares of CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a report on Tuesday, May 5th. Truist Financial boosted their price objective on shares of CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a report on Monday, June 1st. Finally, Leerink Partners reissued an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a report on Thursday, March 5th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $100.68.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Multiple articles highlight CVS as a value opportunity, with commentary that its comeback may be “just getting started” and that the stock still looks cheap relative to its earnings and growth prospects. CVS Health’s Comeback Is Just Getting Started — and Its Valuation Still Looks Shockingly Cheap
• Positive Sentiment: Analyst sentiment remains constructive: Mizuho reportedly raised its price target on CVS due to a more stable policy environment, and Morgan Stanley previously lifted its recommendation to $111 while keeping an Overweight view. Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
• Positive Sentiment: CVS continues to show operational progress, including Aetna’s AI-driven claims tools that reduced processing time by more than 20%, which could support margins and improve customer experience over time. Is CVS Health (CVS) One of Billionaire Larry Robbins’ 10 Dividend Stock Picks?
• Neutral Sentiment: Aetna also announced $130,000 in donations to Kansas City organizations, reinforcing CVS’s community-health positioning, though this is unlikely to move the stock meaningfully on its own. Aetna Donates $130,000 to Kansas City Organizations To Support Nutrition, Mental Health, Maternal Health and Health-Related Social Needs
• Neutral Sentiment: Other coverage, including Zacks and broader “CVS trending” articles, mainly reflects ongoing investor attention rather than a new fundamental catalyst. Zacks.com featured highlights include StoneCo, USANA Health, Strategic Education, Nexa Resources and CVS
• Negative Sentiment: A report on state officials revising the expense outlook for the Mass General Brigham–CVS deal may add some uncertainty around the transaction’s economics, though the market impact appears limited so far. State officials tweak expense outlook on Mass General Brigham, CVS deal

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last quarter. 0.85% of the stock is currently owned by company insiders.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.